Category Archives: General HIV+ population

Reviews on HIV+ people where the population is not specified

Mpox clinical outcomes in people with and without HIV treated with tecovirimat: A systematic review

2026

Mpox poses heightened risks for immunocompromised individuals, particularly people with HIV (PWH), yet evidence on clinical outcomes and antiviral treatment remains limited. We conducted a systematic review in accordance with...

Cardiovascular diseases among people living with HIV/AIDS in Ethiopia: A scoping review

2026

Background Human Immunodeficiency Virus (HIV)/ Acquired Immunodeficiency Syndrome (AIDS) remains a significant burden in Ethiopia. People living with HIV/AIDS (PLWHA) are at increased risk of cardiovascular diseases due to both...

Models of care for women living with HIV in Europe: A scoping review

2026

INTRODUCTION: With the widespread availability of antiretroviral therapy, human immunodeficiency virus (HIV) has become a chronic condition requiring long-term, integrated care. Women with HIV experience distinct clinical, reproductive, and psychosocial...

Relationship between onychomycosis and HIV: A systematic review

2026

Background/Objectives: Onychomycosis is a fungal nail infection that may present with severe, atypical, or treatment-resistant features in people living with HIV. Despite its clinical importance, evidence regarding its epidemiology, causative...

Prevalence of loneliness and social isolation among people living with HIV: A systematic review and meta-analysis

2026

Design A systematic review and meta-analysis. Data Sources PubMed, Cochrane Library, SciELO Citation Index (via Web of Science), Scopus, Embase, PsycArticles, and Cumulative Index to Nursing and Allied Health Literature...

One-year mortality among adults with advanced HIV in sub-Saharan Africa: A systematic review and meta-analysis

2026

Background: In sub-Saharan Africa (SSA), people with HIV continue to present with advanced HIV disease (AHD), putting them at high risk of life-threatening opportunistic diseases. We aimed to estimate mortality...

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: A systematic literature review and network meta-analysis

2026

Aim: With modern antiretroviral therapy (ART), HIV-1 has now become a manageable chronic condition. Among treatment-experienced (TE) people with HIV-1 (PWH), ART regimens can influence metabolic and renal outcomes and...

Perinatal HIV in Europe: Clinical advances and psychosocial challenges—A scoping review

2026

Despite significant biomedical advances in the prevention of mother-to-child transmission (MTCT) of HIV, residual transmission and suboptimal maternal outcomes persist across Europe. The challenge is no longer primarily virological but...

Barriers and facilitators of isoniazid preventive therapy implementation among people living with HIV in Nigeria: A scoping review of the literature

2023

BACKGROUND: Implementation of Isoniazid Preventive Therapy (IPT) among People Living with HIV (PLHIV) continues to be a significant challenge, and there is a shortage of effective interventions. This scoping review...

Cause of death and risk of death for people living with HIV admitted to hospital: A systematic review and meta-analysis

2026

Introduction Despite increasing access to HIV treatment and care, HIV-associated deaths remain high. We aimed to summarize global and regional trends in risk and causes of death among people living...

Prevalence of different genotypes of HIV-1 in injection drug users in China: A systematic review and meta-analysis

2019

Background: Since 1981, an increasing trend in HIV has been observed for transmission via injection drug users (IDUs), sexual transmission and mother-to-child transmission. The IDUs are blamed for early increases...

Efficacy and safety of doravirine/islatravir for HIV-1: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials

2026

Background: The combination of doravirine and islatravir (DOR/ISL) is a novel two-drug regimen for HIV-1. Early development faced challenges due to dose-dependent immunological signals. We aimed to synthesize the evidence on...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!